Completion of Acquisition

RNS Number:8225G
Cytomyx Holdings PLC
23 December 2004


For Immediate Release                                         23 December 2004





                              Cytomyx Holdings Plc



                      Completion of Clinomics Acquisition



The Company is pleased to announce that, further to the passing of the
resolution approving the amendment of the terms of the Clinomics Biosciences,
Inc. ("Clinomics") acquisition to allow an accelerated allotment of the deferred
consideration shares, 1,777,778 ordinary shares of 2.5 pence each in the Company
("Ordinary Shares") have been issued as deferred consideration for the
acquisition and the Company has in addition issued the final tranche of the
initial consideration for Clinomics, comprising 384,835 ordinary shares, which
were with held pending agreement of completion accounts.



As a result the Company has applied for an aggregate of 2,162,613 Ordinary
Shares to be admitted to trading on AIM with effect from 29 December 2004.
Following this issue the Company has 43,954,971 Ordinary Shares in issue.



For further information, please contact:


Cytomyx Holdings plc

Mike Kerins, Chief Executive                                       01223 508191

Buchanan Communications                                           020 7466 5000

Mark Court/Mary-Jane Johnson

The Wall Street Group, Inc.                                     +1 212 888 4848
Ron Stabiner




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

ACQQKNKPABDDCBB

Cytomyx (LSE:CYX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024